AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Article
October 22, 2020

Phenylalanine Effects on Brain Function in Adult Phenylketonuria

Andrea Pilotto, MD https://orcid.org/0000-0003-2029-6606, Carl M. Zipser, MD https://orcid.org/0000-0002-4396-4796, Edytha Leks, MD, Dorothea Haas, MD, Gwendolyn Gramer, MD, Peter Freisinger, MD, Eva Schaeffer, MD, … Show All … , Inga Liepelt-Scarfone, PhD, Kathrin Brockmann, MD, Walter Maetzler, MD, Claudia Schulte, Bio, Christian Deuschle, Ann Kathrin Hauser, Georg F. Hoffmann, MD, Klaus Scheffler, MD, Francjan J. van Spronsen, MD, Alessandro Padovani, MD, PhD, Friedrich Trefz, MD, and Daniela Berg, MDAuthors Info & Affiliations
January 19, 2021 issue
96 (3) e399-e411
https://doi.org/10.1212/WNL.0000000000011088
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Objective

To evaluate the relationship between circulating phenylalanine and brain function as well as neuropsychiatric symptoms in adults with phenylketonuria.

Methods

In this prospective cross-sectional study, early-treated patients with phenylketonuria older than 30 years and age- and sex-matched controls were included. Extensive neurologic evaluation, neuropsychological and behavioral testing, sensory and motor evoked potentials, and MRI were performed. CSF concentrations of neurodegenerative markers were evaluated in addition in a subset of 10 patients.

Results

Nineteen patients with phenylketonuria (median age 41 years) with different phenylalanine levels (median 873 μmol/L) entered the study. They showed higher prevalence of neurologic symptoms, cognitive and behavioral abnormalities, autonomic dysfunction, alterations in neurophysiologic measures, and atrophy in putamen and right thalamus compared to controls. In CSF, patients with phenylketonuria exhibited higher β-amyloid 1-42 (p = 0.003), total tau (p < 0.001), and phosphorylated tau (p = 0.032) levels compared to controls. Plasma phenylalanine levels highly correlated with the number of failed neuropsychological tests (r = 0.64, p = 0.003), neuropsychiatric symptoms (r = 0.73, p < 001), motor evoked potential latency (r = 0.48, p = 0.030), and parietal lobe atrophy.

Conclusions

Our study provides strong evidence for a correlation between phenylalanine levels and clinical, neuropsychological, neurophysiologic, biochemical, and imaging alterations in adult patients with phenylketonuria.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

References

1.
Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417–1427.
Crossref
PubMed
Google Scholar
2.
Feillet F, Van Spronsen FJ, Macdonald A, et al. Challenges and pitfalls in the management of phenylketonuria. Pediatrics 2010;126:333–341.
Crossref
PubMed
Google Scholar
3.
Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, Van Spronsen FJ. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr 2014;164:895–899.e2.
Crossref
PubMed
Google Scholar
4.
Trefz F, Maillot F, Motzfeldt K, Schwarz M. Adult phenylketonuria outcome and management. Mol Genet Metab 2011;104:S26–S30.
Crossref
PubMed
Google Scholar
5.
Trefz FK, van Spronsen FJ, MacDonald A, et al. Management of adult patients with phenylketonuria: survey results from 24 countries. Eur J Pediatr 2015;174:119–127.
Crossref
PubMed
Google Scholar
6.
Perez-Duenas B, Pujol J, Soriano-Mas C, et al. Global and regional volume changes in the brains of patients with phenylketonuria. Neurology 2006;66:1074–1078.
Crossref
PubMed
Google Scholar
7.
Christ SE, Price MH, Bodner KE, et al. Morphometric analysis of gray matter integrity in individuals with early-treated phenylketonuria. Mol Genet Metab 2016;118:3–8.
Crossref
PubMed
Google Scholar
8.
Weglage J, Fromm J, Van Teeffelen-heithoff A, et al. Neurocognitive functioning in adults with phenylketonuria: results of a long term study. Mol Genet Metab 2013;110:S44–S48.
Crossref
PubMed
Google Scholar
9.
Pilotto A, Blau N, Leks E, et al. Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria. J Inherit Metab Dis 2019;42:398–406.
Crossref
PubMed
Google Scholar
10.
Burlina AP, Lachmann RH, Manara R, et al. The neurological and psychological phenotype of adult patients with early-treated phenylketonuria: a systematic review. J Inherit Metab Dis 2019;42:209–219.
Crossref
PubMed
Google Scholar
11.
Bartus A, Palasti F, Juhasz E, et al. The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients. Metab Brain Dis 2018;33:1609–1615.
Crossref
PubMed
Google Scholar
12.
Feillet F, Macdonald A, Hartung D, Burton B. Outcomes beyond phenylalanine: an international perspective. Mol Genet Metab 2010;99:S79–S85.
Crossref
PubMed
Google Scholar
13.
Adler-abramovich L, Vaks L, Carny O, et al. Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat Chem Biol 2012;8:701–706.
Crossref
PubMed
Google Scholar
14.
van Spronsen FJ, van Wegberg AM, Ahring K, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 2017;5:743–756.
Crossref
PubMed
Google Scholar
15.
Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014;16:188–200.
Crossref
PubMed
Google Scholar
16.
Burgard P, Ullrich K, Ballhausen D, et al. Issues with European guidelines for phenylketonuria. Lancet Diabetes Endocrinol 2017;5:681–683.
Crossref
PubMed
Google Scholar
17.
Cannet C, Pilotto A, Rocha JC, et al. Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation. Orphanet J Rare Dis 2020;15:1–7.
Crossref
PubMed
Google Scholar
18.
Pilotto A, Heinzel S, Suenkel U, et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Mov Disord 2017;32:1025–1034.
Crossref
PubMed
Google Scholar
19.
Pilotto A, Turrone R, Liepelt-Scarfone I, et al. Vascular risk factors and cognition in Parkinson's disease. J Alzheimers Dis 2016;51:563–570.
Crossref
PubMed
Google Scholar
20.
Pilotto A, Rossi F, Rinaldi F, et al. Exploring olfactory function and its relation with behavioral and cognitive impairment in amyotrophic lateral sclerosis patients: a cross-sectional study. Neurodegener Dis 2016;16:411–416.
Crossref
PubMed
Google Scholar
21.
Liepelt-Scarfone I, Pilotto A, Müller K, et al. Autonomic dysfunction in subjects at high risk for Parkinson's disease. J Neurol 2015;262:2643–2652.
Crossref
PubMed
Google Scholar
22.
Mills KR, Murray NM. Electrical stimulation over the human vertebral column: which neural elements are excited? Electroencephalogr Clin Neurophysiol 1986;63:582–589.
Crossref
PubMed
Google Scholar
23.
Lerche S, Schulte C, Srulijes K, et al. Cognitive impairment in glucocerebrosidase (GBA)-associated PD: not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Mov Disord 2017;32:1780–1783.
Crossref
PubMed
Google Scholar
24.
Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage 2000;11:805–821.
Crossref
PubMed
Google Scholar
25.
Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–356.
Crossref
PubMed
Google Scholar
26.
Ashburner J, Friston KJ. Computing average shaped tissue probability templates. Neuroimage 2009;45:333–341.
Crossref
PubMed
Google Scholar
27.
Bilder DA, Kobori JA, Cohen-Pfeffer JL, et al. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab 2017;121:1–8.
Crossref
PubMed
Google Scholar
28.
Trefz KF, Muntau AC, Kohlscheen KM, et al. Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities: a retrospective study of German health insurance claims data. Orphanet J Rare Dis 2019;14:181.
Crossref
PubMed
Google Scholar
29.
Boot E, Hollak CEM, Huijbregts SCJ, et al. Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria. Psychol Med 2017;47:2854–2865.
Crossref
PubMed
Google Scholar
30.
Gramer G, Förl B, Springer C, et al. Visual functions in phenylketonuria-evaluating the dopamine and long-chain polyunsaturated fatty acids depletion hypotheses. Mol Genet Metab 2013;108:1–7.
Crossref
PubMed
Google Scholar
31.
Feldmann R, Osterloh J, Onon S, et al. Neurocognitive functioning in adults with phenylketonuria: report of a 10-year follow-up. Mol Genet Metab 2018;126:246–249.
Crossref
PubMed
Google Scholar
32.
Hofman DL, Champ CL, Lawton CL, et al. A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet J Rare Dis 2018;13:150.
Crossref
PubMed
Google Scholar
33.
Ten Hoedt AE, De Sonneville LMJ, Francois B, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis 2011;34:165–171.
Crossref
PubMed
Google Scholar
34.
Anjema K, van Rijn M, Verkerk PH, et al. PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol Genet Metab 2011;104:231–234.
Crossref
PubMed
Google Scholar
35.
Jahja R, van Spronsen FJ, de Sonneville LMJ, et al. Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study. J Inherit Metab Dis 2016;39:355–362.
Crossref
PubMed
Google Scholar
36.
Fereshtehnejad SM, Yao C, Pelletier A, et al. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain 2019;142:2051–2067.
Crossref
PubMed
Google Scholar
37.
Pilotto A, Romagnolo A, Tuazon JA, et al. Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies. J Neurol Neurosurg Psychiatry 2019;90:1257–1263.
Crossref
PubMed
Google Scholar
38.
Evans S, Daly A, Chahal S, et al. The influence of parental food preference and neophobia on children with phenylketonuria (PKU). Mol Genet Metab Rep 2018;14:10–14.
PubMed
Google Scholar
39.
Anderson PJ, Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab 2010;99:S3–S9.
Crossref
PubMed
Google Scholar
40.
van Spronsen FJ, Hoeksma M, Reijngoud DJ. Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause? J Inherit Metab Dis 2009;32:46–51.
Crossref
PubMed
Google Scholar
41.
Vos SJB, Visser PJ, Verhey F, et al. Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. PLoS One 2014;9:e100784.
Crossref
PubMed
Google Scholar
42.
Padovani A, Premi E, Pilotto A, et al. Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study. J Alzheimers Dis 2013;36:49–55.
Crossref
PubMed
Google Scholar
43.
Bacioglu M, Maia LF, Preische O, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases article neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative disease. Neuron 2016;91:494–496.
Crossref
PubMed
Google Scholar
44.
Bodner KE, Aldridge K, Moffitt AJ, et al. A volumetric study of basal ganglia structures in individuals with early-treated phenylketonuria. Mol Genet Metab 2012;107:302–307.
Crossref
PubMed
Google Scholar
45.
Fortea J, Sala-Llonch R, Bartrés-Faz D, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis 2010;22:909–922.
Crossref
PubMed
Google Scholar
46.
Pilotto A, Schiano F, Premi E, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123 I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2019;46:1642–1651.
Crossref
PubMed
Google Scholar
47.
Eriksson J, Vogel EK, Lansner A, et al. Neurocognitive architecture of working memory. Neuron 2015;88:33–46.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 96 • Number 3 • January 19, 2021
Pages: e399-e411
PubMed: 33093221

Copyright

© 2020 American Academy of Neurology.

Publication History

Received: March 5, 2020
Accepted: September 1, 2020
Published online: October 22, 2020
Published in print: January 19, 2021

Permissions

Request permissions for this article.

Disclosure

A. Pilotto received speaker honoraria from BioMarin, Chiesi, Nutricia, UCB, and Zambon Pharmaceuticals; received travel grants from AbbVie, BioMarin, Nutricia, and Zambon Pharmaceuticals; served on the advisory board of Z-cube s.r.l. (Technology Division of Zambon Pharma); and received research support from Vitaflo Germany, Zambon Italy, the Italian Ministry of Health, and H2020 Horizon Program. C.M Zipser and Edyta Leks report no disclosures. D. Haas received speaker honoraria and a travel grant from Sobi. G. Gramer received speaker honoraria from MetaX, Friedberg, Germany, and the Recordati Rare Diseases Foundation, Paris, France. P. Freisinger reports no disclosures. E. Schaeffer reports speaker's honoraria from Bayer Vital GmbH and Novartis as well as intramural research funding for a research rotation position from the University of Kiel outside the submitted work. I. Liepelt-Scarfone reports the following grants: International Parkinson Funds (Deutschland) GmbH (IPD), Michael J. Fox Foundation (MJFF), European Commission, H2020-TWINN-2015, and Jannsen Pharmaceutica N.V. K. Brockmann has received a research grant from the University of Tübingen (Clinician Scientist) and the German Society of Parkinson's disease (DPV), funding from the Michael J. Fox Foundation (MJFF) and the German Centre for Neurodegenerative Diseases (DZNE, MIGAP), travel grants from the Movement Disorders Society, and speaker honoraria from AbbVie, Lundbeck, UCB, and Zambon. W. Maetzler is co-chair of the MDS Technology Task Force and receives or received funding from the European Union, the German Federal Ministry of Education of Research, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Sivantos, Lundbeck, and Janssen; received speaker honoraria from AbbVie, Bayer, GlaxoSmithKline, Licher MT, Rölke Pharma, and UCB; and was invited to Advisory Boards of AbbVie, Biogen, Lundbeck, and Market Access & Pricing Strategy GmbH. C. Schulte, C. Deuschle, and A.K. Hauser report no disclosures. G.F. Hoffmann received speaker honoraria from Danone and Takeda. K. Scheffler report no disclosures. F.J. Van Spronsen is a member of Scientific Advisory Boards for Phenylketonuria (Merck-Serono SA, Arla Foods, Biomarin, APR, Nutricia, Nestle-Codexis Alliance, Moderna), and has received grants from Nutricia, Codexis, Merck-Serono SA, and Biomarin, and honoraria from Merck-Serono SA, Biomarin, Vitaflo International, Nutricia/Danone, and Excemed. A. Padovani received grant support from Ministry of Health (MINSAL) and Ministry of Education, Research and University (MIUR), CARIPLO Foundation, Zambon, Italy; and personal compensation as a consultant/scientific advisory board member for Avanir, Lundbeck, Eli-Lilly, Neuraxpharma, Biogen, and GE Health. F. Trefz reports grants from Vitaflo Germany; personal compensation for advisory board of Biomarin Pharma; and honoraria as a speaker from Merck-Serono SA and Biomarin Pharma. D. Berg reports grants from Michael J. Fox Foundation, Janssen Pharmaceutica N.V., German Parkinson's Disease Association, BMWi, BMBF, Parkinson Fonds Deutschland GmbH, UCB Pharma GmbH, Teva Pharma GmbH, EU, Novartis Pharma GmbH, and Lundbeck; received personal fees from Advisory board of UCB Pharma GmbH, Lundbeck, Prexton Therapeutics, and GE-Healthcare; and received honoraria from UCB Pharma GmbH, Lundbeck, BIAL, and Bayer. Go to Neurology.org/N for full disclosures.

Study Funding

The study was partially supported by Vitaflo Germany. The company did not have access to the findings and did not have any influence on interpretation of the results.

Authors

Affiliations & Disclosures

Andrea Pilotto, MD https://orcid.org/0000-0003-2029-6606
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
Served on Advisory BOard of Z-cube (Technology Division of Zambon Pharma
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Andrea Pilotto received honoraria from the UCB Pharma, Zambon, Nutricia and Chiesi pharmaceuticals
Editorial Boards:
1.
Frontiers in Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Vitaflo Germany, Zambon Italy
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Italian Ministry of Health, IMI initiative (H2020 program)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Carl M. Zipser, MD https://orcid.org/0000-0002-4396-4796
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Edytha Leks, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Dorothea Haas, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Vitaflo: travel funding and Speaker honoraria to speak at a conference(2) Dr. Schär: travel funding and honoraria for scientific chairmanship at a conference(3) SOBI: travel Funding and Speaker honoraria to speak at a conference
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gwendolyn Gramer, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Non-Profit Entity: International Society for Neonatal Screening (ISNS), Dussault Medal, Price money used for travel costs for ISNS annual meeting
Editorial Boards:
1.
Member Editorial board International Journal of Neonatal Screening
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Research grants from Dietmar Hopp Foundation, St. Leon-Rot, Germany (Non-Profit Entity)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Peter Freisinger, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
(1) Biomarin, Germany
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Biomarin Germany(2) Dr. Schaer, Germany
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Vitaflo,Germany
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Eva Schaeffer, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speakers honoraria from Bayer Vital GmbH and Novartis.
Editorial Boards:
1.
Frontiers in Neurology, Review Editor, 2020
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Intramural research funding from the University of Kiel.
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Inga Liepelt-Scarfone, PhD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Non-profi: Deutsche Parkinson Gesellschaft, Speaker Honoraria
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Johnson & Johnson, unrestricted grant
Research Support, Government Entities:
1.
(1)German Ministry for Education and Research, Projektnumber 01GI1008C; local PI: 2016-2017(2)European Commission, H2020-TWINN-2015, Grant Agreementnumber: 692320 ? CENTRE-PD, Nr. 692320, PI, 2016-2019
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1)International Parkinson Fonds (Deutschland) GmbH (IPD)(2)Fonds National de la Recherche Luxembourg(3)Michael J Fox Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Kathrin Brockmann, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
KB has received honoraria for lectures fromGlaxoSmithKline, Lundbeck, Orion Pharma, UCB, and Zambonas well as travel grants from the Movement Disorders Society.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
BMBF
Research Support, Academic Entities:
1.
1. the University of Tuebingen (Clinician Scientist) 2. the German Centre for Neurodegenerative Diseases (DZNE, MIGAP).
Research Support, Foundations and Societies:
1.
1. the German Society of Parkinson?s disease (dpv); 2. the Michael J. Fox Foundation (MJFF)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Walter Maetzler, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
(1) Advisory Boards of Market Access & Pricing Strategy GmbH (2) Abbvie(3) Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Neuro-Kolleg Online-Live, Rölke Pharma, Takeda and UCB.
Editorial Boards:
1.
PLOS ONE,associate editor, 2014-2016
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) UCB(2) Lundbeck (3) Janssen(4) Sivantos
Research Support, Government Entities:
1.
(1) European Union (Moving beyond, no. 316639, 2012-2016;Scientific coordinator)(2) European Union (Keep Control, no. 721577, 2017-2021;Scientific coordinator)(3) European Union (IMI project Mobilise-D, no 820820, 2019-2024; Cohort lead for PD)(4) European Union (IMI project IDEA-FAST, no 953091, 2019-2025; Co-Coordinator)
Research Support, Academic Entities:
1.
University of Tübingen (doctoral student grants;2006-2014; PI).
Research Support, Foundations and Societies:
1.
Michael J. Fox Foundation (Inflammatory Parkinsonphenotype, 2013-2014; Co-PI)Robert Bosch Foundation (Geriatric aspects of Parkinsondisease, 2008-2011; PI)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Claudia Schulte, Bio
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christian Deuschle
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ann Kathrin Hauser
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Georg F. Hoffmann, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
Editorial board of Journal of Inherited Metabolic DiseasesEditorial advisory boards for Monatsschrift Kinderheilkunde, World Journal of Pediatrics and Kinderneurologie in Klinik und Praxis
Patents:
1.
NONE
Publishing Royalties:
1.
1) Sarafoglou, K., Hoffmann, G.F. und Roth, K.S. 2017 Pediatric Endocrinology and Inborn Errors of Metabolism. The McGraw-Hill Companies Medical2) Hoffmann, G.F., Zschocke, J., Nyhan, W.L. 2017 Inherited Metabolic Diseases, Springer, Heidelberg, Germany
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Klaus Scheffler, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
I design helicopters
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Francjan J. van Spronsen, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
(1) Nutricia(2) Biomarin(3) Homology(4) Pluvia(5) Agios(6) Vivet(7) Nestle-Codexis
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
commercial grants received from(1) Nutricia(2) Biomarin(3) Vitaflo
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Dutch PKU SocietyDutch Tyrosinemia type I Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Alessandro Padovani, MD, PhD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
Avanir, Lundbeck, Eli-Lilly, Neuraxpharma, Biogen, GE Health
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
ZAMBON Pharma Italy
Research Support, Government Entities:
1.
from Ministry of Health (MINSAL) and Ministryof Education, Research and University (MIUR) ;
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
CARIPLO Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Friedrich Trefz, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
BiomarinPharma
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Merck-Serono SA and BiomarinPharma
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Vitaflo Germany
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Daniela Berg, MD
From the Neurology Unit (A. Pilotto, A. Padovani), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Neurodegeneration (A. Pilotto, I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Hertie Institute of Clinical Brain Research (A. Pilotto, C.M.Z., I.L.-S., K.B., W.M., C.S., C.D., A.K.H., D.B.), Department of Neurology and Stroke (C.M.Z.), Department of Biomedical Magnetic Resonance (E.L., K.S.), and German Center for Neurodegenerative Diseases (I.L.-S., K.B., C.S., C.D., A.K.H., K.S.), University of Tübingen, Germany; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS, S. Isidoro Hospital, Trescore Balneario, Italy; Department of Pediatrics (D.H., G.G., G.F.H., F.T.), Division for Neuropediatrics and Metabolic Medicine, University of Heidelberg; Department of Pediatrics (P.F., F.T.), Reutlingen Hospital; Department of Neurology (E.S., W.M., D.B.), University-Hospital-Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel; and Division of Metabolic Diseases (F.J.v.S.), Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, the Netherlands.
Disclosure
Scientific Advisory Boards:
1.
(1) Biogen, (2) BIAL, (3) Lundbeck, (4) UCB Pharma GmbH
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1)Desitin, travel and speaker honoraria(2)Pfizer, travel(3)Lundbeck, travel and speaker honoraria(4)Boehringer Ingelheim Pharma GmbH, travel(5)Coppenrath Stiftung, travel(6)Grünenthal GmbH, travel(7)JPND Research, travel(8)Apothekenwirtschaftsdienst GmbH, travel and speaker honoraria(9) Asklepios Kliniken Hamburg GmbH, travel and speaker honoraria(10)Bayer Vital GmbH, travel and speaker honoraria(11)BIAl Deutschland GmbH, travel and speaker honoraria(12)J. Weser GmbH (Zambon), travel and spaeker honoraria(13)AbbVie Deutschland GmbH, travel and Speaker honoraria(14)TEVA GmbH, travel and Speaker honoraria(15)Dekanat der CAU, travel(16)Ärztekammer Schleswig-Holstein,travel and Speaker honoraria(17) Deutsche Parkinson Vereinigung (DPV), travel and Speaker honoraria(18)Jansen Neuroscience Network, travel and Speaker honoraria(19)Uniklinik RWTH Aachen, travel(20)Humanitas Research Hospital Mailand, travel(21)Universitätsmedizin Rostock, travel(22)Deutsche Gesellschaft für Neurologie (DGN), travel(23)Universitätsklinik Tübingen, travel(24)Aklepios-Klinik Altona, travel and Speaker honoraria(25)NDR-Fernsehen, travel and Speaker honoraria(26)Segeberger Kliniken, travel(27)Deutsche Parkinson Gesellschaft (DPG), travel(28)Scandinavian Movement Disorder Society, travel(29)International Parkinson and Movement Disorder Society, travel and speaker honoraria
Editorial Boards:
1.
(1) DGNeurologie, Funding-Co-Editor,(2) Movement Disorders Clinical Practice Journal, Editorial Board,(3) Neurological Research and Practice, Editorial Board(4) Journal of Parkinsons's Disease, Associate Editor(5) Der Nervenarzt, Member of the Scientific Advisory Board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Biogen(2) BIAL(3) Lundbeck(4) UCB Pharma GmbH
Speakers' Bureaus:
1.
(1)AbbVie(2)Biogen(3)BIAL(4)Lundbeck(5)UCB Pharma GmbH
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1)Janssen Pharmaceutica N.V.(2)UCB Pharma GmbH(3)Novartis Pharma GmbH(4)Lundbeck
Research Support, Government Entities:
1.
(1)BMWi(2)EU
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1)Michael J.Fox Foundation(2)German Parkinson Disease Society (dPG)(3)Damp foundation(4)ParkinsonFonds
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Pilotto [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Sara Stankovic,
    • Andrijana Lazic,
    • Marina Parezanovic,
    • Milena Stevanovic,
    • Sonja Pavlovic,
    • Maja Stojiljkovic,
    • Kristel Klaassen,
    Transcriptome Profiling of Phenylalanine-Treated Human Neuronal Model: Spotlight on Neurite Impairment and Synaptic Connectivity, International Journal of Molecular Sciences, 25, 18, (10019), (2024).https://doi.org/10.3390/ijms251810019
    Crossref
    • Virginie Vignard,
    • Alban-Elouen Baruteau,
    • Bérénice Toutain,
    • Sandra Mercier,
    • Bertrand Isidor,
    • Richard Redon,
    • Jean-Jacques Schott,
    • Sébastien Küry,
    • Stéphane Bézieau,
    • Anne H. Monsoro-Burq,
    • Frédéric Ebstein,
    Exploring the origins of neurodevelopmental proteasomopathies associated with cardiac malformations: are neural crest cells central to certain pathological mechanisms?, Frontiers in Cell and Developmental Biology, 12, (2024).https://doi.org/10.3389/fcell.2024.1370905
    Crossref
    • Kaleigh B. Whitehall,
    • Sarah Rose,
    • Gillian E. Clague,
    • Kirsten K. Ahring,
    • Deborah A. Bilder,
    • Cary O. Harding,
    • Álvaro Hermida,
    • Anita Inwood,
    • Nicola Longo,
    • François Maillot,
    • Ania C. Muntau,
    • André L. S. Pessoa,
    • Júlio C. Rocha,
    • Fran Rohr,
    • Serap Sivri,
    • Jack Said,
    • Sheun Oshinbolu,
    • Gillian C. Sibbring,
    Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria, Orphanet Journal of Rare Diseases, 19, 1, (2024).https://doi.org/10.1186/s13023-024-03203-z
    Crossref
    • Jèssica Pardo,
    • Clara Capdevila-Lacasa,
    • Bàrbara Segura,
    • Adriana Pané,
    • Cristina Montserrat,
    • Maria de Talló Forga-Visa,
    • Pedro J. Moreno,
    • Glòria Garrabou,
    • Josep M. Grau-Junyent,
    • Carme Junqué,
    • Ana Argudo-Ramírez,
    • Blanca Barrau-Martínez,
    • Judith Cantó,
    • Jaume Campistol,
    • Francesc Cardellach,
    • Climent Casals-Pascual,
    • Gemma Chiva-Blanch,
    • Dolores García-Arenas,
    • Francesc Josep García-García,
    • Judit García-Villoria,
    • José Manuel González de Aledo-Castillo,
    • Arnau González-Rodríguez,
    • Mariona Guitart-Mampel,
    • Paula Isern,
    • Amanda Jiménez,
    • Berta Laudo,
    • Rafael Llorach,
    • Félix Andújar-Sánchez,
    • Rosa López-Galera,
    • Silvia Mª Meavilla,
    • José Cesar Milisenda,
    • Blai Morales,
    • Pedro Juan Moreno-Lozano,
    • Julián Moreno,
    • Mònica Nos,
    • Aida Ormazabal,
    • Montserrat Ortega Ferrer,
    • Emilio Ortega,
    • Joan Padrosa,
    • Abraham José Paredes,
    • Elisa Rubio,
    • Ester Tobías,
    • Josep Torremade,
    • Mireia Urpi-Sarda,
    • Laura Valls,
    • Roser Ventura,
    • Andrea Vergara-Gómez,
    • Judith Viaplana,
    • Clara Viñals,
    Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels, Journal of Neurodevelopmental Disorders, 16, 1, (2024).https://doi.org/10.1186/s11689-024-09553-w
    Crossref
    • Raphaela Muri,
    • Christian Rummel,
    • Richard McKinley,
    • Michael Rebsamen,
    • Stephanie Maissen-Abgottspon,
    • Roland Kreis,
    • Piotr Radojewski,
    • Katarzyna Pospieszny,
    • Michel Hochuli,
    • Roland Wiest,
    • Roman Trepp,
    • Regula Everts,
    Transient brain structure changes after high phenylalanine exposure in adults with phenylketonuria, Brain, 147, 11, (3863-3873), (2024).https://doi.org/10.1093/brain/awae139
    Crossref
    • Giovanni Luca Russo,
    • Sharon Puleo,
    • Silvana Cavella,
    • Iris Scala,
    • Marcello Fidaleo,
    • Rossella Di Monaco,
    Advancements in food science for Phenylketonuria (PKU) management: a comprehensive review, Critical Reviews in Food Science and Nutrition, (1-15), (2024).https://doi.org/10.1080/10408398.2024.2360075
    Crossref
    • Friedrich Trefz,
    • Georg Frauendienst-Egger,
    • Gerald Dienel,
    • Claire Cannet,
    • Brigitte Schmidt-Mader,
    • Dorothea Haas,
    • Nenad Blau,
    • Nastassja Himmelreich,
    • Manfred Spraul,
    • Peter Freisinger,
    • Steven Dobrowolski,
    • Daniela Berg,
    • Andrea Pilotto,
    Does hyperphenylalaninemia induce brain glucose hypometabolism? Cerebral spinal fluid findings in treated adult phenylketonuric patients, Molecular Genetics and Metabolism, 142, 1, (108464), (2024).https://doi.org/10.1016/j.ymgme.2024.108464
    Crossref
    • Zhizhong Hu,
    • Yingchun Han,
    • Maorong Hu,
    • Honglin Zhang,
    • Xin Yuan,
    • Huijuan Yu,
    A comparative study of cognitive function in young patients with bipolar disorder with and without non-suicidal self-injury, Acta Psychologica, 243, (104137), (2024).https://doi.org/10.1016/j.actpsy.2024.104137
    Crossref
    • Maxime Brachet,
    • Sybil Charrière,
    • Claire Douillard,
    • François Feillet,
    • Alain Fouilhoux,
    • Leonardo Astudillo,
    • Christian Lavigne,
    • Jean-Baptiste Arnoux,
    • Sylvie Odent,
    • Claire Gay,
    • Manuel Schiff,
    • Karin Mazodier,
    • Alice Kuster,
    • Vincent Rigalleau,
    • Christel Thauvin-Robinet,
    • Vanessa Leguy-Seguin,
    • Valérie Gissot,
    • François Maillot,
    Neuropsychological profile of French adults with early-treated phenylketonuria: a multicenter study, Journal of Neurology, 272, 1, (2024).https://doi.org/10.1007/s00415-024-12840-0
    Crossref
    • Júlio César Rocha,
    • Kirsten K. Ahring,
    • Heather Bausell,
    • Deborah A. Bilder,
    • Cary O. Harding,
    • Anita Inwood,
    • Nicola Longo,
    • Ania C. Muntau,
    • André L. Santos Pessoa,
    • Fran Rohr,
    • Serap Sivri,
    • Álvaro Hermida,
    Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria, Nutrients, 15, 18, (3940), (2023).https://doi.org/10.3390/nu15183940
    Crossref
  11. See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF